At what enterprise value was AMEDES acquired in 2021?

During the acquisition of AMEDES by OMERS in 2021, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of AMEDES when it was acquired by OMERS?

The exact EV/EBITDA multiple for AMEDES is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was AMEDES acquired by OMERS?

AMEDES was acquired by OMERS in 2021.

What was the revenue of AMEDES at the time of the deal?

The revenue of AMEDES at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the AMEDES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the AMEDES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cfnewsinfra.net/L-actualite/LBO/LBO-ter/amedes-post-Antin-IP-double-de-valeur-436529

← DATABASE

Home Database Healthcare & PharmaAMEDES

07/2021

AMEDES acquired by OMERS

GERMANY Health Providers / Healthcare Facilities / Labs (Biology) EV 1b - 4b EUR

Context

A consortium led by Goldman Sachs Asset Management and OMERS Infrastructure acquired amedes from Antin Infrastructure Partners. The transaction valued roughly doubling its value since Antin's entry in 2015. The deal aims to support amedes' continued growth through digitalization and further consolidation of the European lab market.

As a reminder, the company was previously involved in a leveraged buyout led by Antin Infrastructure in 2015.

AMEDES, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Amedes is one of the leading platforms for medical diagnostics in Germany. It has 35 laboratories and 27 practices across Germany and Belgium.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with AMEDES

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2015	ANTIN INFRASTRUCTURE	AMEDES	GERMANY	Health Providers	Antin Infrastructure Partners acquired a majority stake in Amedes Group from General Atlantic. The transaction provided an exit for General Atlantic, which had owned the asset since 2007 and tripled its revenues through a buy-and-build strategy (30+ acquisitions). For Antin, this investment represents a classic "infrastructure" play in the healthcare sector: high recurring revenue (almost 100% repeat usage) due to sticky relationships between doctors and labs, and low volume volatility.

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AMEDES by OMERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: omers